Putative neuroleptic malignant syndrome associated with sertraline withdrawal

Journal of Clinical Psychopharmacology

Volumn 29, Issue 3, 2009, Pages 300-301

  Konstantakopoulos, George ^a   Kouzoupis, Anastasios V ^a   Papageorgiou, Sokratis G ^a   Oulis, Panagiotis ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; DIAZEPAM; LEVODOPA; SERTRALINE;

ADD ON THERAPY; AGED; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERPYREXIA; LABORATORY TEST; LETTER; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION;

AGED; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 67649297919     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a39101     Document Type: Letter

References (18)

1. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142:1137-1145.
2. Ebadi M, Pfeiffer RF, Murrin LC. Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol. 1990;21:367-386.
3. Assion HJ, Heinemann F, Laux G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci. 1998;248:231-239.
4. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry. 1996;29:159-161.
5. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf. 2003;2:21-35.
6. Brunelle J, Guigueno S, Gouin P, et al. Aripiprazole and neuroleptic malignant syndrome. J Clin Psychopharmacol. 2007;27:212-213.
7. Mizuno Y, Takubo H, Mizuta E, et al. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord. 2003;9:S3-S9.
8. Nemeroff CB, Owens MJ. Pharmacologic differences among the SSRIs: focus on monamine transporters and the HPA axis. CNS Spectr. 2004;9(suppl 4):23-31.
9. Nierenberg D, Disch M, Manheimer E, et al. Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clin Pharmacol Ther. 1991;50:580-586.
10. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
11. Lane R, Baldwin D. Selective serotonin reuptake inhibitors induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17:208-221.
12. Fink M, Taylor MA. Catatonia: A Clinicians' Guide to Diagnosis and Treatment. Cambridge, UK: Cambridge University Press; 2003.
13. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 1996;39:1-4.
14. Northoff G, Steinke R, Czcervenka C, et al. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J Neurol Neurosurg Psychiatry. 1999;67:445-450.
15. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry. 1990;28:518-521.
16. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42:1290-1297.
17. Deslandes PN, Pache DM, Buckland P, et al. Morphine, cocaine and antidepressant induced motivational activity and midbrain dopaminergic neurotransmission. Eur J Pharmacol. 2002;453:223-229.
18. Berardi D, Amore M, Keck PE, et al. Clinical and pharmacologic risk factors of neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44:748-754.